Asthma Affecting Patents (Class 514/1.7)
  • Publication number: 20110152169
    Abstract: The invention provides methods of treating a mammal afflicted with an inflammatory disease, such as peritonitis, peritoneal adhesions or endometriosis, comprising the administration, intraperitoneal or otherwise, of a therapeutically effective amount of a SPARC polypeptide or a SPARC polypeptide-encoding isolated polynucleotide and a pharmacologic carrier.
    Type: Application
    Filed: April 14, 2009
    Publication date: June 23, 2011
    Inventors: Kouros Motamed, Vuong Trieu
  • Publication number: 20110152172
    Abstract: Disclosed are methods of treating or preventing a pulmonary disease or disorder in a subject, the methods comprising administering an effective amount of an compound that inhibits Calmodulin Kinase II (CaMKII) activity, either directly or indirectly, thereby treating or preventing the pulmonary disease or disorder in the subject.
    Type: Application
    Filed: June 22, 2010
    Publication date: June 23, 2011
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Mark E. Anderson, Isabella M. Grumbach, Joel N. Kline
  • Publication number: 20110152174
    Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.
    Type: Application
    Filed: February 7, 2011
    Publication date: June 23, 2011
    Applicant: SYNTAXIN LIMITED
    Inventors: Keith Alan FOSTER, John Andrew CHADDOCK, Conrad Padraig QUINN, John Robert PURKISS
  • Publication number: 20110150785
    Abstract: Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder.
    Type: Application
    Filed: January 20, 2011
    Publication date: June 23, 2011
    Applicant: La Jolla Institute for Allergy and Immunology
    Inventors: Michael Croft, Taylor Doherty, Shahram Salek-Ardakani
  • Publication number: 20110152173
    Abstract: This disclosure provides a multi-target fusion protein composed of a TNF-? antagonist domain and another binding domain antagonistic for a heterologous target, such as IL6, RANKL, IL7, IL17A/F, TWEAK, CSF2, IGF1, IGF2 or BLyS/APRIL, or agonistic for a heterologous target, such as IL10. The multi-specific fusion protein may also include an intervening domain that separates the binding domains and allows for dimerization. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.
    Type: Application
    Filed: July 2, 2009
    Publication date: June 23, 2011
    Inventors: Alan Keith Lofquist, Kendall Mark Mohler, Peter Robert Baum, Peter Armstrong Thompson, Lynda Misher
  • Publication number: 20110143995
    Abstract: The present invention discloses novel complex molecules useful as anti-allergic agents. These complex molecules include in particular, peptidic or peptidomimetic molecules, having a first segment which is competent for cell penetration and a second segment which is able to reduce or abolish mast cell degranulation, and in particular to reduce or abolish allergy mediators such as histamine secretion from mast cells. Specific examples of peptides with the desired activity are disclosed.
    Type: Application
    Filed: November 9, 2010
    Publication date: June 16, 2011
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Ronit Eisenberg, Tamar Raz
  • Publication number: 20110142884
    Abstract: Provided are methods of treatment of many different diseases and disorders using micelle and sterically stabilized crystalline compounds of the invention.
    Type: Application
    Filed: July 14, 2010
    Publication date: June 16, 2011
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Hayat Onyuksel, Israel Rubinstein
  • Publication number: 20110143994
    Abstract: The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically the invention relates to new immuno-modulating complexes which are fusion proteins comprising mutant subunits of bacterial endotoxins, a peptide capable of binding to a specific cellular receptor, and one or more epitopes associated with an autoimmune or allergic disease.
    Type: Application
    Filed: December 15, 2008
    Publication date: June 16, 2011
    Inventor: Nils Lycke
  • Publication number: 20110143992
    Abstract: Disclosed herein are methods and compositions related to GHS-R antagonists.
    Type: Application
    Filed: February 13, 2007
    Publication date: June 16, 2011
    Inventors: Dennis Taub, Vishwa Deep Dixit
  • Publication number: 20110123530
    Abstract: Compositions, kits and methods for treating and diagnosing subtypes of asthma patients are provided. Also provided are methods for identifying effective asthma therapeutic agents and predicting responsiveness to asthma therapeutic agents.
    Type: Application
    Filed: March 31, 2009
    Publication date: May 26, 2011
    Inventors: Joseph R. Arron, John V. Fahy, Barmak Modrek, Prescott Woodruff
  • Patent number: 7947648
    Abstract: The present invention relates generally to methods and compounds for treating pulmonary disorders, and more specifically to the inhalation administration and use of hIL-4 mutant proteins to treat asthma.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: May 24, 2011
    Assignee: Aerovance, Inc.
    Inventors: Jeffrey Tepper, Adrian Tomkinson
  • Publication number: 20110117106
    Abstract: Calpains target junctional components that normally seal the epithelium, forming tight junctions. This selective targeting by calpains facilitates the transmigration of leukocytes across the epithelium and into tissue spaces where they can cause inflammation. The present disclosure provides methods of using calpain inhibitors to prevent epithelial junction reorganization such that leukocyte transmigration is inhibited and accordingly, inflammation reduced or prevented. These methods can at least be used to reduce respiratory inflammation by preventing leukocyte accumulation in pulmonary airways.
    Type: Application
    Filed: March 6, 2009
    Publication date: May 19, 2011
    Inventor: Alice Prince
  • Publication number: 20110112011
    Abstract: Disclosed are pharmaceutical compositions containing, as active ingredients, a mixture of a corticosteroid and a kinin B2 receptor antagonist. Said compositions have proved particularly effective, especially in the treatment of inflammatory disorders such as asthma, ophthalmic or dermatological disorders and, above all, as regards the joints, arthritis.
    Type: Application
    Filed: July 3, 2009
    Publication date: May 12, 2011
    Applicant: ISTITUTO LUSO FARMACO D'ITALIA S.P.A.
    Inventors: Sandro Giuliani, Carlo Alberto Maggi
  • Publication number: 20110104217
    Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.
    Type: Application
    Filed: December 14, 2010
    Publication date: May 5, 2011
    Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Galit Rotman, Michal Ayalon-Soffer
  • Publication number: 20110104263
    Abstract: The disclosure provides methods and compositions useful for treating claudin-4 associated disorders including cell proliferative disorders. The disclosure also provide claudin-family binding peptides useful in the methods of the disclosure.
    Type: Application
    Filed: April 30, 2009
    Publication date: May 5, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David D. Lo, Jun Ling, Mary M. Hamer, Thejani Rajapaksa
  • Publication number: 20110107443
    Abstract: This invention relates to novel protein transduction domains (PTDs) derived from secretory leukocyte protease inhibitor (SLPI). SLPI-derived PTDs are able to deliver cargo moieties in vivo and in vitro into the cytoplasm and nucleus of a host cell. The invention also relates to a transduction complex comprising one or more SLPI-derived PTDs linked or fused to one or more cargo moieties, which may comprise, for example, proteins, nucleic acids, lipids, carbohydrates, small molecules and other chemical compounds. The invention also relates to the manufacture of SLPI-derived PTDs, complexes comprising them; compositions comprising SLPI-derived PTDs or complexes; and utilization of SLPI-derived PTDs or complexes comprising them for therapeutic, diagnostic and research methods involving delivery of heterologous molecules across cellular membranes, and especially, across nuclear membranes.
    Type: Application
    Filed: October 2, 2008
    Publication date: May 5, 2011
    Inventors: Marie T. Filbin, Sari Hannila
  • Publication number: 20110098212
    Abstract: A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and HIV/AIDS, are described.
    Type: Application
    Filed: May 25, 2006
    Publication date: April 28, 2011
    Inventors: Ursula Gompels, Julie Catusse, David Dewin
  • Patent number: 7931898
    Abstract: The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: April 26, 2011
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Eugene Regis Krah, III, Robert Lawton
  • Publication number: 20110082073
    Abstract: The present invention relates to isolated Cpn10 polypeptides possessing an increased affinity for a PRR ligand compared to Ala Cpn10 polypeptide. In a further embodiment, the present invention also relates to modified chaperonin 10 polypeptides, and to nucleic acids encoding the same and to compositions comprising such polypeptides and uses thereof.
    Type: Application
    Filed: April 9, 2009
    Publication date: April 7, 2011
    Applicant: CBIO LIMITED
    Inventors: Dean Jason Naylor, Richard James Brown, Christopher Bruce Howard, Christopher John De Bakker, Linda Alisson Ward, Jeanette Elizabeth Stok, Andrew Leigh James, Daniel Scott Lambert, Kylie Jane Ralston, Walter Rene Antonius Van Heumen
  • Publication number: 20110081344
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: November 10, 2010
    Publication date: April 7, 2011
    Inventors: Wayne R. Kindsvogel, Stavros Topouzis
  • Publication number: 20110077191
    Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.
    Type: Application
    Filed: October 20, 2008
    Publication date: March 31, 2011
    Applicant: Alba Therapeutics Corporation
    Inventor: Amir Tamiz
  • Publication number: 20110077190
    Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
    Type: Application
    Filed: May 21, 2009
    Publication date: March 31, 2011
    Inventors: Jan-Eric Ahlfors, Khalid Mekouar
  • Publication number: 20110064728
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: June 28, 2010
    Publication date: March 17, 2011
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Audrey Goddard, Paul Godowski, J. Christopher Grimaldi, Austin Gumey, Hanzhong Li, Kenneth Hillan, Sarah G. Hymowitz, Daniel Tumas, Melissa A. Starovasnik, Menno VanLookeren, Richard Vandlen, Colin Watanabe, P. Mickey Williams, William I. Wood, Daniel Yansura
  • Publication number: 20110061114
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245, PRO246, PRO258, PRO287, PRO328, PRO344, PRO357, PRO526, PRO724, PRO731, PRO732, PRO1003, PRO1104, PRO1151, PRO1244, PRO1298, PRO1313, PRO1570, PRO1886, PRO1891, PRO4409, PRO5725, PRO5994, PRO6097, PRO7425, PRO10102, PRO10282, PRO61709 or PRO779 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
    Type: Application
    Filed: November 12, 2010
    Publication date: March 10, 2011
    Inventors: JOEL A. EDWARDS, Charles Montgomery, Zheng-Zheng Shi, Mary Jean Sparks
  • Publication number: 20110059885
    Abstract: The method of the invention relates to an OmCI polypeptide or a polynucleotide encoding an OmCI polypeptide for the treatment of a disease or condition mediated by a leukotriene or hydroxyeicosanoid.
    Type: Application
    Filed: February 5, 2009
    Publication date: March 10, 2011
    Inventors: Susan Lea, Miles Nunn, Pietro Roversi
  • Publication number: 20110052729
    Abstract: The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.
    Type: Application
    Filed: August 26, 2010
    Publication date: March 3, 2011
    Inventor: Jeffrey M. Golini
  • Publication number: 20110052616
    Abstract: The present invention concerns a peptide molecule or a nucleic acid molecule, for use in medicine and, in particular, for use in preventing or treating a non-cancerous condition or relieving pain in a patient. The invention also relates to a pharmaceutical composition comprising the peptide or nucleic acid molecule of the invention and methods of treatment thereof.
    Type: Application
    Filed: February 25, 2009
    Publication date: March 3, 2011
    Applicant: Helperby Therapeutics Limited
    Inventors: Anthony Robert Milnes Coates, Yanira Riffo-Vasquez, Peter Tormay
  • Publication number: 20110038885
    Abstract: The present invention is directed to peptide analogs of chemokine, the pharmaceutically acceptable salts thereof, to methods of using such analogs to treat mammals and to pharmaceutical compositions useful therefor comprising said analogs.
    Type: Application
    Filed: July 21, 2008
    Publication date: February 17, 2011
    Inventors: Zheng Xin Dong, Sun H. Kim
  • Publication number: 20110033521
    Abstract: Molecules and compositions including same for the isolation of MCP-1 and treatment of CCR2/MCP-1 associated diseases.
    Type: Application
    Filed: April 10, 2006
    Publication date: February 10, 2011
    Applicant: Rappaport Family Institute for Research in the Medical Sciences
    Inventors: Nathan Karin, Gizi Wildbaum, Yaniv Zohar, Liat Izhak, Uri Weinberg
  • Publication number: 20110027315
    Abstract: The present disclosure provides compositions comprising a protein cage and methods for using the protein cage compositions to induce an immune protection response, or to prevent or ameliorate a viral or a bacterial infection.
    Type: Application
    Filed: September 5, 2008
    Publication date: February 3, 2011
    Inventors: Allen Harmsen, Trevor Douglas, Mark Young
  • Publication number: 20110014128
    Abstract: The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and/or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed.
    Type: Application
    Filed: July 15, 2010
    Publication date: January 20, 2011
    Inventors: Sylvain Chemtob, Christiane Quiniou, Martin Beauchamp
  • Publication number: 20110008284
    Abstract: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.
    Type: Application
    Filed: July 8, 2010
    Publication date: January 13, 2011
    Inventors: Xuri Gao, Yat Sun Or, Guoqiang Wang, Jiang Long
  • Publication number: 20110008251
    Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.
    Type: Application
    Filed: May 19, 2009
    Publication date: January 13, 2011
    Applicant: IBC PHARMACEUTICALS, INC.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Publication number: 20110008285
    Abstract: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.
    Type: Application
    Filed: July 8, 2010
    Publication date: January 13, 2011
    Inventors: Jiang Long, Yat Sun Or, Xuri Gao, Guoqiang Wang
  • Publication number: 20110008269
    Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.
    Type: Application
    Filed: August 9, 2010
    Publication date: January 13, 2011
    Inventor: Michael M. Grunstein
  • Publication number: 20110008286
    Abstract: The present invention provides novel proline substituted cyclosporinanalogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.
    Type: Application
    Filed: July 8, 2010
    Publication date: January 13, 2011
    Inventors: Guoqiang Wang, Yat Sun Or, Jiang Long, Xuri Gao
  • Publication number: 20110002854
    Abstract: A pharmaceutical composition for treating or preventing a Th2-mediated disease or disorder includes live, killed or attentuated Franciscella tularensis or its components. The F. tularensis cells may be LVS cells. Administration of an effective amount may prevent or reduce bronchoconstriction or allergic airway inflammation through a T-helper cell (Th) 1-mediated suppression of an ongoing Th2 response mechanism.
    Type: Application
    Filed: March 20, 2008
    Publication date: January 6, 2011
    Applicant: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Wangxue Chen, Girishchandra Babubhai Patel
  • Publication number: 20100331237
    Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably ?1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.
    Type: Application
    Filed: August 18, 2010
    Publication date: December 30, 2010
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventor: Andreas J. KUNGL
  • Publication number: 20100331236
    Abstract: The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.
    Type: Application
    Filed: July 14, 2009
    Publication date: December 30, 2010
    Applicants: PROMICS PTY LIMITED, UNIQUEST PTY LIMITED
    Inventors: Stephen Maxwell Taylor, Ian Alexander Shiels, David Fairlie, Darren March, Michael Whitehouse
  • Publication number: 20100316628
    Abstract: The present invention relates to a novel method of preventing and/or treating respiratory disorders and respiratory-related complications in a subject by inhibiting the release of nitric oxide from basal cells in the respiratory tract.
    Type: Application
    Filed: December 9, 2009
    Publication date: December 16, 2010
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Sylvie Breton, Dennis Brown, Wai Chi Shum, Nicolas Da Silva
  • Publication number: 20100311644
    Abstract: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of ?PKC are also disclosed.
    Type: Application
    Filed: May 24, 2010
    Publication date: December 9, 2010
    Inventor: Daria Mochly-Rosen
  • Publication number: 20100305024
    Abstract: The present invention provides a method of modulating calcineurin activity in a cell by contacting the cell with at least one ApoE analog. Methods of treating various disorders associated with calcineurin activity using one or more ApoE analogs are also disclosed. In particular, the present invention provides a method of reducing demyelination and promoting remyelination in a subject. Methods of treating spinal cord or nerve injury in a subject are also described.
    Type: Application
    Filed: July 31, 2008
    Publication date: December 2, 2010
    Inventors: Michael P. Vitek, Feng-Qiao Li
  • Publication number: 20100279922
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: July 10, 2006
    Publication date: November 4, 2010
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
  • Publication number: 20100267615
    Abstract: The present invention is directed to methods for treatment and/or prevention of a disease associated with vascular leak in a patient comprising administering to the patient an effective amount of SEQ ID NO: 1.
    Type: Application
    Filed: June 3, 2010
    Publication date: October 21, 2010
    Applicant: FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH
    Inventors: Peter Petzelbauer, Rainer Henning, Sonja Reingruber, Waltraud Pasteiner, Marion Gröger
  • Publication number: 20100256043
    Abstract: The present invention is directed to the use of the peptide compound Glu-Ala-Leu-Glu-Leu-Ala-Arg-Gly-Ala-Ile-Phe-Gln-Ala-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Glu-Ala-Leu-Glu-Leu-Ala-Arg-Gly-Ala-Ile-Phe-Gln-Ala-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
    Type: Application
    Filed: September 9, 2008
    Publication date: October 7, 2010
    Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
  • Publication number: 20100249017
    Abstract: The present invention is directed to the use of the peptide compound Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
    Type: Application
    Filed: September 9, 2008
    Publication date: September 30, 2010
    Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher